Chapter/Section Purchase

1 Chemotherapy Induced Neutropenia Drug Market Overview
1.1 Product Overview and Scope of Chemotherapy Induced Neutropenia Drug
1.2 Chemotherapy Induced Neutropenia Drug Segment by Type
1.2.1 Global Chemotherapy Induced Neutropenia Drug Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 F-627
1.2.3 BBT-018
1.2.4 Filgrastim
1.2.5 GW-003
1.2.6 NLA-101
1.2.7 Others
1.3 Chemotherapy Induced Neutropenia Drug Segment by Application
1.3.1 Global Chemotherapy Induced Neutropenia Drug Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Chemotherapy Induced Neutropenia Drug Market Size Estimates and Forecasts
1.4.1 Global Chemotherapy Induced Neutropenia Drug Revenue 2017-2028
1.4.2 Global Chemotherapy Induced Neutropenia Drug Sales 2017-2028
1.4.3 Chemotherapy Induced Neutropenia Drug Market Size by Region: 2017 Versus 2021 Versus 2028
2 Chemotherapy Induced Neutropenia Drug Market Competition by Manufacturers
2.1 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Manufacturers (2017-2022)
2.2 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Chemotherapy Induced Neutropenia Drug Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Chemotherapy Induced Neutropenia Drug Manufacturing Sites, Area Served, Product Type
2.5 Chemotherapy Induced Neutropenia Drug Market Competitive Situation and Trends
2.5.1 Chemotherapy Induced Neutropenia Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Chemotherapy Induced Neutropenia Drug Players Market Share by Revenue
2.5.3 Global Chemotherapy Induced Neutropenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario by Region
3.1 Global Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Chemotherapy Induced Neutropenia Drug Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
3.3.1 North America Chemotherapy Induced Neutropenia Drug Sales by Country
3.3.2 North America Chemotherapy Induced Neutropenia Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
3.4.1 Europe Chemotherapy Induced Neutropenia Drug Sales by Country
3.4.2 Europe Chemotherapy Induced Neutropenia Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Chemotherapy Induced Neutropenia Drug Sales by Region
3.5.2 Asia Pacific Chemotherapy Induced Neutropenia Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
3.6.1 Latin America Chemotherapy Induced Neutropenia Drug Sales by Country
3.6.2 Latin America Chemotherapy Induced Neutropenia Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Chemotherapy Induced Neutropenia Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Chemotherapy Induced Neutropenia Drug Sales by Country
3.7.2 Middle East and Africa Chemotherapy Induced Neutropenia Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Chemotherapy Induced Neutropenia Drug Historic Market Analysis by Type
4.1 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Type (2017-2022)
4.2 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Type (2017-2022)
4.3 Global Chemotherapy Induced Neutropenia Drug Price by Type (2017-2022)
5 Global Chemotherapy Induced Neutropenia Drug Historic Market Analysis by Application
5.1 Global Chemotherapy Induced Neutropenia Drug Sales Market Share by Application (2017-2022)
5.2 Global Chemotherapy Induced Neutropenia Drug Revenue Market Share by Application (2017-2022)
5.3 Global Chemotherapy Induced Neutropenia Drug Price by Application (2017-2022)
6 Key Companies Profiled
6.1 BeyondSpring Pharmaceuticals Inc
6.1.1 BeyondSpring Pharmaceuticals Inc Corporation Information
6.1.2 BeyondSpring Pharmaceuticals Inc Description and Business Overview
6.1.3 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.1.4 BeyondSpring Pharmaceuticals Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.1.5 BeyondSpring Pharmaceuticals Inc Recent Developments/Updates
6.2 Biocon Ltd
6.2.1 Biocon Ltd Corporation Information
6.2.2 Biocon Ltd Description and Business Overview
6.2.3 Biocon Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Biocon Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.2.5 Biocon Ltd Recent Developments/Updates
6.3 Bolder Biotechnology Inc
6.3.1 Bolder Biotechnology Inc Corporation Information
6.3.2 Bolder Biotechnology Inc Description and Business Overview
6.3.3 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Bolder Biotechnology Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.3.5 Bolder Biotechnology Inc Recent Developments/Updates
6.4 Cellerant Therapeutics Inc
6.4.1 Cellerant Therapeutics Inc Corporation Information
6.4.2 Cellerant Therapeutics Inc Description and Business Overview
6.4.3 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Cellerant Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.4.5 Cellerant Therapeutics Inc Recent Developments/Updates
6.5 Chong Kun Dang Pharmaceutical Corp
6.5.1 Chong Kun Dang Pharmaceutical Corp Corporation Information
6.5.2 Chong Kun Dang Pharmaceutical Corp Description and Business Overview
6.5.3 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Chong Kun Dang Pharmaceutical Corp Chemotherapy Induced Neutropenia Drug Product Portfolio
6.5.5 Chong Kun Dang Pharmaceutical Corp Recent Developments/Updates
6.6 Cinfa Biotech SL
6.6.1 Cinfa Biotech SL Corporation Information
6.6.2 Cinfa Biotech SL Description and Business Overview
6.6.3 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Cinfa Biotech SL Chemotherapy Induced Neutropenia Drug Product Portfolio
6.6.5 Cinfa Biotech SL Recent Developments/Updates
6.7 Dr. Reddy's Laboratories Ltd
6.6.1 Dr. Reddy's Laboratories Ltd Corporation Information
6.6.2 Dr. Reddy's Laboratories Ltd Description and Business Overview
6.6.3 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Dr. Reddy's Laboratories Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.7.5 Dr. Reddy's Laboratories Ltd Recent Developments/Updates
6.8 Gene Techno Science Co Ltd
6.8.1 Gene Techno Science Co Ltd Corporation Information
6.8.2 Gene Techno Science Co Ltd Description and Business Overview
6.8.3 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Gene Techno Science Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.8.5 Gene Techno Science Co Ltd Recent Developments/Updates
6.9 Generon (Shanghai) Corp Ltd
6.9.1 Generon (Shanghai) Corp Ltd Corporation Information
6.9.2 Generon (Shanghai) Corp Ltd Description and Business Overview
6.9.3 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Generon (Shanghai) Corp Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.9.5 Generon (Shanghai) Corp Ltd Recent Developments/Updates
6.10 Genexine Inc
6.10.1 Genexine Inc Corporation Information
6.10.2 Genexine Inc Description and Business Overview
6.10.3 Genexine Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Genexine Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.10.5 Genexine Inc Recent Developments/Updates
6.11 GlycoMimetics Inc
6.11.1 GlycoMimetics Inc Corporation Information
6.11.2 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.11.3 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.11.4 GlycoMimetics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.11.5 GlycoMimetics Inc Recent Developments/Updates
6.12 Hanmi Pharmaceuticals Co Ltd
6.12.1 Hanmi Pharmaceuticals Co Ltd Corporation Information
6.12.2 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.12.3 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Hanmi Pharmaceuticals Co Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.12.5 Hanmi Pharmaceuticals Co Ltd Recent Developments/Updates
6.13 Intas Pharmaceuticals Ltd
6.13.1 Intas Pharmaceuticals Ltd Corporation Information
6.13.2 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.13.3 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Intas Pharmaceuticals Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.13.5 Intas Pharmaceuticals Ltd Recent Developments/Updates
6.14 Lupin Ltd
6.14.1 Lupin Ltd Corporation Information
6.14.2 Lupin Ltd Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.14.3 Lupin Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Lupin Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.14.5 Lupin Ltd Recent Developments/Updates
6.15 Mycenax Biotech Inc
6.15.1 Mycenax Biotech Inc Corporation Information
6.15.2 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.15.3 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Mycenax Biotech Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.15.5 Mycenax Biotech Inc Recent Developments/Updates
6.16 Myelo Therapeutics GmbH
6.16.1 Myelo Therapeutics GmbH Corporation Information
6.16.2 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.16.3 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Myelo Therapeutics GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
6.16.5 Myelo Therapeutics GmbH Recent Developments/Updates
6.17 Nohla Therapeutics Inc
6.17.1 Nohla Therapeutics Inc Corporation Information
6.17.2 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.17.3 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Nohla Therapeutics Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.17.5 Nohla Therapeutics Inc Recent Developments/Updates
6.18 Octapharma AG
6.18.1 Octapharma AG Corporation Information
6.18.2 Octapharma AG Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.18.3 Octapharma AG Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Octapharma AG Chemotherapy Induced Neutropenia Drug Product Portfolio
6.18.5 Octapharma AG Recent Developments/Updates
6.19 Pangen Biotech Inc.
6.19.1 Pangen Biotech Inc. Corporation Information
6.19.2 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.19.3 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Pangen Biotech Inc. Chemotherapy Induced Neutropenia Drug Product Portfolio
6.19.5 Pangen Biotech Inc. Recent Developments/Updates
6.20 Pfenex Inc
6.20.1 Pfenex Inc Corporation Information
6.20.2 Pfenex Inc Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.20.3 Pfenex Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Pfenex Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.20.5 Pfenex Inc Recent Developments/Updates
6.21 Pfizer Inc
6.21.1 Pfizer Inc Corporation Information
6.21.2 Pfizer Inc Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.21.3 Pfizer Inc Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.21.4 Pfizer Inc Chemotherapy Induced Neutropenia Drug Product Portfolio
6.21.5 Pfizer Inc Recent Developments/Updates
6.22 Reliance Life Sciences Pvt Ltd
6.22.1 Reliance Life Sciences Pvt Ltd Corporation Information
6.22.2 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.22.3 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.22.4 Reliance Life Sciences Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.22.5 Reliance Life Sciences Pvt Ltd Recent Developments/Updates
6.23 Richter Gedeon Nyrt
6.23.1 Richter Gedeon Nyrt Corporation Information
6.23.2 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.23.3 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.23.4 Richter Gedeon Nyrt Chemotherapy Induced Neutropenia Drug Product Portfolio
6.23.5 Richter Gedeon Nyrt Recent Developments/Updates
6.24 Sandoz International GmbH
6.24.1 Sandoz International GmbH Corporation Information
6.24.2 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.24.3 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.24.4 Sandoz International GmbH Chemotherapy Induced Neutropenia Drug Product Portfolio
6.24.5 Sandoz International GmbH Recent Developments/Updates
6.25 USV Pvt Ltd
6.25.1 USV Pvt Ltd Corporation Information
6.25.2 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Description and Business Overview
6.25.3 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Sales, Revenue and Gross Margin (2017-2022)
6.25.4 USV Pvt Ltd Chemotherapy Induced Neutropenia Drug Product Portfolio
6.25.5 USV Pvt Ltd Recent Developments/Updates
7 Chemotherapy Induced Neutropenia Drug Manufacturing Cost Analysis
7.1 Chemotherapy Induced Neutropenia Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Chemotherapy Induced Neutropenia Drug
7.4 Chemotherapy Induced Neutropenia Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Chemotherapy Induced Neutropenia Drug Distributors List
8.3 Chemotherapy Induced Neutropenia Drug Customers
9 Chemotherapy Induced Neutropenia Drug Market Dynamics
9.1 Chemotherapy Induced Neutropenia Drug Industry Trends
9.2 Chemotherapy Induced Neutropenia Drug Market Drivers
9.3 Chemotherapy Induced Neutropenia Drug Market Challenges
9.4 Chemotherapy Induced Neutropenia Drug Market Restraints
10 Global Market Forecast
10.1 Chemotherapy Induced Neutropenia Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Chemotherapy Induced Neutropenia Drug by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Chemotherapy Induced Neutropenia Drug by Type (2023-2028)
10.2 Chemotherapy Induced Neutropenia Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Chemotherapy Induced Neutropenia Drug by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Chemotherapy Induced Neutropenia Drug by Application (2023-2028)
10.3 Chemotherapy Induced Neutropenia Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Chemotherapy Induced Neutropenia Drug by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Chemotherapy Induced Neutropenia Drug by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer